[ad_1]
The company's rheumatoid arthritis drug appeared to reduce the risk of contracting Alzheimer's disease by 64%. Washington Row's Chris Rowland explains why Pfizer did not pursue it. Learn more: https://wapo.st/2JVdegV. Subscribe to The Washington Post on YouTube: https://wapo.st/2QOdcqK
Follow us:
Twitter: https://twitter.com/washingtonpost
Instagram: https://www.instagram.com/washingtonp …
Facebook: https://www.facebook.com/washingtonpost/
[ad_2]
Source link
